Horm Metab Res 2019; 51(09): 586-594
DOI: 10.1055/a-0957-3297
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

The Spectrum of Genetic Defects in Congenital Adrenal Hyperplasia in the Population of Cyprus: A Retrospective Analysis

Vassos Neocleous
1   Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
2   Cyprus School of Molecular Medicine, Nicosia, Cyprus
,
Pavlos Fanis
1   Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
2   Cyprus School of Molecular Medicine, Nicosia, Cyprus
,
Meropi Toumba
1   Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
3   Pediatric Endocrine Clinic, IASIS Hospital, Paphos, Cyprus
,
Charilaos Stylianou
4   Division of Pediatric Endocrinology, Makarios III Hospital, Nicosia, Cyprus
,
Michalis Picolos
5   Alithias Endocrinology Center, Nicosia, Cyprus
,
Elena Andreou
6   Dasoupolis Endocrinology Center, Andrea Dimitriou Street Dasoupolis, Nicosia, Cyprus
,
Andreas Kyriakou
7   Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Glasgow, UK
,
Michalis Iasonides
8   Iliaktida Peadiatric & Adolescent Medical Centre, Limassol, Cyprus
,
Stella Nicolaou
4   Division of Pediatric Endocrinology, Makarios III Hospital, Nicosia, Cyprus
,
Tassos C. Kyriakides
9   Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
,
George A. Tanteles
2   Cyprus School of Molecular Medicine, Nicosia, Cyprus
10   Department of Clinical Genetics, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
,
Nicos Skordis
1   Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
11   Division of Pediatric Endocrinology, Paedi Center for Specialized Pediatrics, Nicosia, Cyprus
12   St George’s, University of London Medical School at the University of Nicosia, Nicosia, Cyprus
,
Leonidas A. Phylactou
1   Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
2   Cyprus School of Molecular Medicine, Nicosia, Cyprus
› Author Affiliations
Further Information

Publication History

received 18 March 2019

accepted 06 June 2019

Publication Date:
10 September 2019 (online)

Abstract

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is caused by mutations in the CYP21A2 gene. The study refers to CAH patients of Greek-Cypriot ancestry between years 2007 and 2018. One hundred and twenty patients with various degrees of CAH were categorized and genotyped. The patients were categorized in 4 mutation groups based on their clinical and biochemical findings. The majority of patients (85.0%) belonged to the non-classic (NC)-CAH form and the disorder was more often diagnosed in females (71.7%). The most severe classic salt-wasting (SW) form was identified in 11 neonates (9.2%). Seven (5.8%) children were also identified with the simple virilizing (SV) form and a median presentation age of 5 years [interquartile range (IQR) 3.2–6.5]. In the 240 nonrelated alleles, the most frequent mutation was p.Val281Leu (60.0%) followed by c.655 A/C>G (IVS2–13A/C>G) (8.8%), p.Pro453Ser (5.8%), DelEx1–3 (4.6%), p.Val304Met (4.6%), and p.Gln318stop (4.2%). Other less frequent mutations including rare deletions were also identified. Following our recent report that the true carrier frequency of CYP21A2 in Greek-Cypriots is 1:10, this study reports that the CAH prevalence is predicted around 1.7 cases per 10 000 people. Therefore, the up-to-date 120 CAH patients identified by our group make only the 6.9% of the ones estimated (approximately 1750) to exist in the Greek Cypriot population. The compiled data from a coherent population such as the Greek-Cypriot could be valuable for the antenatal diagnosis, management and genetic counselling of the existing and prospect families with CAH.

 
  • References

  • 1 Speiser PW, Dupont J, Zhu D. et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 90: 584-595
  • 2 White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291
  • 3 Wedell A, Thilen A, Ritzen EM. et al. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: Implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab 1994; 78: 1145-1152
  • 4 Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord 2009; 10: 77-82
  • 5 New MI, Abraham M, Gonzalez B. et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA 2013; 110: 2611-2616
  • 6 Haider S, Islam B, D'Atri V. et al. Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia. Proc Natl Acad Sci USA 2013; 110: 2605-2610
  • 7 Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365: 2125-2136
  • 8 Fitness J, Dixit N, Webster D. et al. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 84: 960-966
  • 9 Baumgartner-Parzer SM, Nowotny P, Heinze G. et al. Carrier frequency of congenital adrenal hyperplasia (21-hydroxylase deficiency) in a middle European population. J Clin Endocrinol Metab 2005; 90: 775-778
  • 10 Phedonos AA, Shammas C, Skordis N. et al. High carrier frequency of 21-hydroxylase deficiency in Cyprus. Clin Genet 2013; 84: 585-588
  • 11 Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23: 181-192
  • 12 Balsamo A, Baldazzi L, Menabo S. et al. Impact of molecular genetics on congenital adrenal hyperplasia management. Sex Develop 2010; 4: 233-248
  • 13 Concolino P, Costella A. Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene. Mol Diagn Ther 2018; 22: 261-280
  • 14 Neocleous V, Ioannou YS, Bartsota M. et al. Rare mutations in the CYP21A2 gene detected in congenital adrenal hyperplasia. Clin Biochem 2009; 42: 1363-1367
  • 15 Skordis N, Kyriakou A, Tardy V. et al. Molecular defects of the CYP21A2 gene in Greek-Cypriot patients with congenital adrenal hyperplasia. Horm Res Paediatr 2011; 75: 180-186
  • 16 Skordis N, Shammas C, Efstathiou E. et al. Endocrine profile and phenotype-genotype correlation in unrelated patients with non-classical congenital adrenal hyperplasia. Clin Biochem 2011; 44: 959-963
  • 17 Skordis N, Shammas C, Phedonos AA. et al. Genetic defects of the CYP21A2 gene in girls with premature adrenarche. J Endocrinol Invest 2015; 38: 535-539
  • 18 Neocleous V, Fanis P, Phylactou LA. et al. Genotype is associated to the degree of virilization in patients with classic congenital adrenal hyperplasia. Front Endocrinol 2018; 9: 733
  • 19 Neocleous V, Shammas C, Phedonos AA. et al. Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations. Indian J Endocrinol Metab 2014; 18: S72-S79
  • 20 Neocleous V, Portides G, Anastasiadou V. et al. Determination of the carrier frequency of the common GJB2 (connexin-26) 35delG mutation in the Greek Cypriot population. Int J Pediatr Otorhinolaryngol 2006; 70: 1473-1477
  • 21 Neocleous V, Fanis P, Toumba M. et al. Variations in the 3'UTR of the CYP21A2 Gene in heterozygous females with hyperandrogenaemia. Int J Endocrinol 2017; 8984365
  • 22 Greene CN, Cordovado SK, Turner DP. et al. Novel method to characterize CYP21A2 in Florida patients with congenital adrenal hyperplasia and commercially available cell lines. Mol Genet Metab Rep 2014; 1: 312-323
  • 23 Tusie-Luna MT, Traktman P, White PC. Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 1990; 265: 20916-20922
  • 24 Wilson RC, Mercado AB, Cheng KC. et al. Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 1995; 80: 2322-2329
  • 25 Wedell A. Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): Implications for diagnosis, prognosis and treatment. Acta Paediatr 1998; 87: 159-164
  • 26 Higashi Y, Tanae A, Inoue H. et al. Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450(C21) gene: Implications for steroid 21-hydroxylase deficiency. Am J Hum Genet 1988; 42: 17-25
  • 27 Rodrigues NR, Dunham I, Yu CY. et al. Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J 1987; 6: 1653-1661
  • 28 Higashi Y, Hiromasa T, Tanae A. et al. Effects of individual mutations in the P-450(C21) pseudogene on the P-450(C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem 1991; 109: 638-644
  • 29 Amor M, Parker KL, Globerman H. et al. Mutation in the CYP21B gene (Ile-172–Asn) causes steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA 1988; 85: 1600-1604
  • 30 Barbaro M, Baldazzi L, Balsamo A. et al. Functional studies of two novel and two rare mutations in the 21-hydroxylase gene. J Mol Med (Berl) 2006; 84: 521-528
  • 31 Lajic S, Robins T, Krone N. et al. CYP21 mutations in simple virilizing congenital adrenal hyperplasia. J Mol Med (Berl) 2001; 79: 581-586
  • 32 Balsamo A, Cacciari E, Baldazzi L. et al. CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region. Clin Endocrinol (Oxf) 2000; 53: 117-125
  • 33 Lekarev O, Tafuri K, Lane AH. et al. Erroneous prenatal diagnosis of congenital adrenal hyperplasia owing to a duplication of the CYP21A2 gene. J Perinatol 2013; 33: 76-78
  • 34 Speiser PW, Arlt W, Auchus RJ. et al. Congenital Adrenal Hyperplasia Due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018; 103: 4043-4088
  • 35 Meyer-Bahlburg HFL, Khuri J, Reyes-Portillo J. et al. Stigma associated with classical congenital adrenal hyperplasia in women’s sexual lives. Arch Sex Behav 2018; 47: 943-951
  • 36 Bachelot A, Grouthier V, Courtillot C. et al. Management of endocrine disease: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Update on the management of adult patients and prenatal treatment. Eur J Endocrinol 2017; 176: R167-R181
  • 37 Gidlof S, Falhammar H, Thilen A. et al. One hundred years of congenital adrenal hyperplasia in Sweden: A retrospective, population-based cohort study. Lancet Diabetes Endocrinol 2013; 1: 35-42
  • 38 Arlt W, Willis DS, Wild SH. et al. Health status of adults with congenital adrenal hyperplasia: A cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95: 5110-5121
  • 39 El-Maouche D, Arlt W, Merke DP. Congenital adrenal hyperplasia. Lancet 2017; 390: 2194-2210
  • 40 Parsa AA, New MI. Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 2017; 165: 2-11
  • 41 Shammas C, Neocleous V, Toumba M. et al. Overview of genetic defects in endocrinopathies in the island of Cyprus; Evidence of a founder effect. Genet Test Mol Biomark 2012; 16: 1073-1079
  • 42 Wilson RC, Nimkarn S, Dumic M. et al. Ethnic-specific distribution of mutations in 716 patients with congenital adrenal hyperplasia owing to 21–hydroxylase deficiency. Mol Genet Metab 2007; 90: 414-421
  • 43 Ayalon-Dangur I, Segev-Becker A, Ayalon I. et al. The many faces of non-classic congenital adrenal hyperplasia. Isr Med Assoc J 2017; 19: 317-322
  • 44 Eyal O, Tenenbaum-Rakover Y, Shalitin S. et al. Adult height of subjects with nonclassical 21-hydroxylase deficiency. Acta Paediatr 2013; 102: 419-423
  • 45 Neocleous V, Shammas C, Phedonos AP. et al. Genetic defects in the cyp21a2 gene in heterozygous girls with premature adrenarche and adolescent females with hyperandrogenemia. Georgian Med News 2012; 40-47
  • 46 Dracopoulou-Vabouli M, Maniati-Christidi M, Dacou-Voutetakis C. The spectrum of molecular defects of the CYP21 gene in the Hellenic population: Variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001; 86: 2845-2848
  • 47 Sadeghi F, Yurur-Kutlay N, Berberoglu M. et al. Identification of frequency and distribution of the nine most frequent mutations among patients with 21-hydroxylase deficiency in Turkey. J Pediatr Endocrinol Metab 2008; 21: 781-787
  • 48 Ezquieta B, Oliver A, Gracia R. et al. Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. Hum Genet 1995; 96: 198-204
  • 49 Carrera P, Bordone L, Azzani T. et al. Point mutations in Italian patients with classic, non-classic, and cryptic forms of steroid 21-hydroxylase deficiency. Hum Genet 1996; 98: 662-665
  • 50 Lee HH. The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency. J Hum Genet 2004; 49: 65-72
  • 51 Concolino P, Mello E, Minucci A. et al. A new CYP21A1P/CYP21A2 chimeric gene identified in an Italian woman suffering from classical congenital adrenal hyperplasia form. BMC Med Genet 2009; 10: 72